Unusual lymphoid malignancy and treatment response in two children with Down syndrome.
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Burkitt Lymphoma
/ diagnosis
Child
Child, Preschool
Cyclophosphamide
/ administration & dosage
Cytarabine
/ administration & dosage
Down Syndrome
Herpesvirus 4, Human
Humans
Male
Methotrexate
/ administration & dosage
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
/ diagnosis
T-Lymphocytes
/ virology
Burkitt lymphoma
Down syndrome
EBV
lymphoproliferative disorder
methotrexate
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
08
03
2019
revised:
07
05
2019
accepted:
08
05
2019
pubmed:
29
5
2019
medline:
23
1
2020
entrez:
29
5
2019
Statut:
ppublish
Résumé
Lymphoid malignancies other than acute lymphoblastic leukemia (ALL) are rare in children with Down syndrome (DS). Information about the toxicity of chemotherapy and prognosis is largely derived from the experience of children with DS and ALL or children without DS. We describe the treatment and outcome of two unusual lymphoid malignancies in children with DS. One patient was diagnosed with Burkitt lymphoma (BL) and the second, after treatment for B precursor ALL, with T-cell EBV-positive proliferative disorder (LPD). BL was treated with standard doses of LMB group B therapy subsequently intensified to group C therapy, including high-dose methotrexate (HD-MTX, 3-8 g/m Upfront reduction of the high treatment intensity, which is associated with excellent survival outcomes in BL, may not be warranted in all children with DS. Response to therapy and prognosis of T-cell EBV-positive LPD in a patient with DS was not predicted by reported experience in the absence of DS.
Sections du résumé
BACKGROUND
Lymphoid malignancies other than acute lymphoblastic leukemia (ALL) are rare in children with Down syndrome (DS). Information about the toxicity of chemotherapy and prognosis is largely derived from the experience of children with DS and ALL or children without DS.
PROCEDURE
We describe the treatment and outcome of two unusual lymphoid malignancies in children with DS. One patient was diagnosed with Burkitt lymphoma (BL) and the second, after treatment for B precursor ALL, with T-cell EBV-positive proliferative disorder (LPD).
RESULTS
BL was treated with standard doses of LMB group B therapy subsequently intensified to group C therapy, including high-dose methotrexate (HD-MTX, 3-8 g/m
CONCLUSIONS
Upfront reduction of the high treatment intensity, which is associated with excellent survival outcomes in BL, may not be warranted in all children with DS. Response to therapy and prognosis of T-cell EBV-positive LPD in a patient with DS was not predicted by reported experience in the absence of DS.
Substances chimiques
Cytarabine
04079A1RDZ
Cyclophosphamide
8N3DW7272P
Methotrexate
YL5FZ2Y5U1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27822Informations de copyright
© 2019 Wiley Periodicals, Inc.